BioVie Inc. (BIVI) Stock Score, Valuation & Financial Research

BioVie Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for BIVI

BioVie Inc. does not currently have a complete Wall Street Score. The stored market price is USD 1.52. These figures are a research snapshot, not a buy or sell recommendation.

What BioVie Inc. does

BioVie Inc. is a clinical-stage biotechnology firm primarily dedicated to the discovery, development, and commercialization of innovative drug treatments across the United States. The company's developmental portfolio includes BIV201, a therapeutic agent that has successfully completed its Phase IIa clinical trial for addressing ascites resulting from chronic liver cirrhosis. Additionally, BioVie is advancing NE3107, which is currently undergoing a Phase III clinical trial for the management of mild to moderate Alzheimer's disease, and is also in a Phase I clinical trial for the treatment of Parkinson's disease. Further preclinical investigations are underway for NE3107, exploring its potential applications in treating multiple myeloma and prostate cancer. Established in 2013, the company adopted its current name, BioVie Inc., in July 2016, having previously operated as NanoAntibiotics, Inc. Its corporate headquarters are situated in Carson City, Nevada.

Company business and revenue

Research reporting period: 2026-06-30. A research update is not a new financial filing.

How the company makes money

BioVie Inc. is a clinical-stage biopharmaceutical company that does not currently generate product revenue. Its business model relies on raising capital to fund research and development, clinical trials, and regulatory processes for its drug candidates, with the goal of eventually commercializing therapies for neurodegenerative and liver diseases.

Products and services

  • The company is developing bezisterim (NE3107) for Alzheimer's disease, Parkinson’s disease, and long COVID, and BIV201 (continuous infusion terlipressin) for liver cirrhosis and ascites.

Brands and product families

  • Bezisterim (NE3107) — Lead drug candidate for neurodegenerative diseases and long COVID. Source
  • BIV201 — Drug candidate for liver cirrhosis and ascites. Source

Customer types

Healthcare providers and patients.

Suppliers, materials and equipment

  • Contract Research Organizations (CROs) and Contract Manufacturing Organizations (CMOs) — The company relies on third-party service providers for clinical trial management, data collection, and drug manufacturing; specific supplier names are not disclosed. Source

Business strengths to evaluate

  • Clinical-stage pipeline targeting high-unmet-need conditions like Alzheimer's and liver cirrhosis Source

Business risks and research considerations

  • No history of product revenue and dependence on additional financing to continue operations Source
  • Uncertainty regarding regulatory approval and clinical trial success for drug candidates Source

Sources: Company research source

Company research refreshed 2026-10-13. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

BIVI financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 1.52
Market capitalization:
11.46M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -22.07M
Free cash flow:
USD -19.02B
Cash:
USD 8.98M
Total debt:
USD 275.43K
EPS:
USD -3.20

What stands out

  • Free cash flow is USD -19.02B, negative for the stored period.
  • The balance sheet shows USD 8.98M of cash versus USD 275.43K of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a corporate distress warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 8.7M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for BIVI

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can BIVI fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is BIVI likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for BIVI to reach sustainable profitability?
  • What does the current corporate distress warning mean for the reliability or interpretation of BIVI's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research BIVI

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.